In This Article:
As global markets reach new heights, with indices like the Russell 2000 hitting record intraday highs, investor sentiment remains buoyed by domestic policy developments and easing geopolitical tensions. In this environment, identifying high-growth tech stocks that can capitalize on current economic trends and technological advancements is crucial for investors seeking to navigate the evolving landscape of December 2024.
Top 10 High Growth Tech Companies
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Material Group | 20.45% | 24.01% | ★★★★★★ |
| Ascelia Pharma | 76.15% | 47.16% | ★★★★★★ |
| Waystream Holding | 22.09% | 113.25% | ★★★★★★ |
| Pharma Mar | 28.04% | 56.19% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.35% | 70.33% | ★★★★★★ |
| TG Therapeutics | 34.66% | 56.98% | ★★★★★★ |
| Elliptic Laboratories | 70.09% | 111.37% | ★★★★★★ |
| Alkami Technology | 21.89% | 98.60% | ★★★★★★ |
| Travere Therapeutics | 31.70% | 72.51% | ★★★★★★ |
| Initiator Pharma | 73.95% | 31.67% | ★★★★★★ |
Click here to see the full list of 1285 stocks from our High Growth Tech and AI Stocks screener.
Let's review some notable picks from our screened stocks.
Grifols
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Grifols, S.A. is a plasma therapeutic company with operations in Spain, the United States, Canada, and internationally, and has a market cap of €5.32 billion.
Operations: Grifols generates revenue primarily from its Biopharma segment, which accounts for €5.95 billion, followed by the Diagnostic and Bio Supplies segments at €651.33 million and €204.55 million, respectively.
Grifols, a player in the biotech sector, has demonstrated robust financial performance with earnings skyrocketing by 590.4% over the past year, significantly outpacing its industry's average decline of 18.2%. Despite these gains, its projected annual revenue growth at 6% lags behind the broader tech sector's expectations but surpasses Spain's market growth rate of 4.9%. The company is poised for substantial future earnings growth, forecasted at an impressive rate of 33.9% annually. This financial trajectory is underpinned by Grifols' strategic emphasis on R&D investments which have fostered innovation and sustained competitive advantages in biotechnology and pharmaceuticals.
-
Dive into the specifics of Grifols here with our thorough health report.
-
Explore historical data to track Grifols' performance over time in our Past section.
Shanghai BOCHU Electronic Technology
Simply Wall St Growth Rating: ★★★★★★
Overview: Shanghai BOCHU Electronic Technology Corporation Limited operates in the electronic technology sector and has a market capitalization of CN¥36.73 billion.
Operations: Shanghai BOCHU Electronic Technology focuses on the electronic technology sector, generating revenue primarily through its diverse range of electronic products and services. The company has experienced fluctuations in its net profit margin, which is currently at 12.5%.